15302 Psoriasis area and severity index component improvements at week 48 in patients treated with guselkumab compared with secukinumab: Findings from the ECLIPSE study

Abstract

Background: Guselkumab (GUS), a fully human monoclonal antibody targeting interleukin-23, is approved to treat moderate to severe plaque psoriasis. In the ECLIPSE trial, GUS demonstrated a superior Psoriasis Area and Severity Index (PASI) 90 response compared with the interleukin-17A inhibitor secukinumab (SEC) at week 48. This subanalysis assessed PASI component responses at week 48.